PURPOSE: This is a report of the surgical treatment and prognosis of retroperitoneal liposarcoma (RPLS) in Koreans. MATERIALS AND METHODS: Nineteen patients treated for RPLS between July 1, 1984, and March 31, 2009, were included. Patient demographics, histopathologic subtypes, survival rate, disease recurrence rate and interval, and adjuvant therapy were reviewed and analyzed. RESULTS: Of the 19 patients diagnosed with RPLS, 26.3% presented with well-differentiated RPLS, 10.5% with dedifferentiated RPLS, 15.8% with myxoid/round cell type, and 47.4% with mixed-type liposarcoma. The mean follow-up period was 66.8 months (range, 6 to 165 months). Primary RPLS was treated in 17 patients. Nine patients (52.9%) had recurrent disease, and recurrence developed at a mean of 47.7 months after primary or repeated surgical treatment. The overall survival rate was 84.2% during a mean follow-up of 66.8 months. The 3- and 5-year survival rates were 86.9%, and the 10-year survival rate was 69.5%. The recurrence interval was significantly shorter in recurrent RPLS cases (p=0.023). The mean growth rate of locally recurrent tumors was 0.34 cm per month. CONCLUSIONS: The survival rates reported here were higher than in previous studies. Locally recurrent tumors presented with a low growth rate, which may have contributed to the relatively high survival rate. A high prevalence of mixed-type RPLS was also noted, and its cause and prognosis require further research.
PURPOSE: This is a report of the surgical treatment and prognosis of retroperitoneal liposarcoma (RPLS) in Koreans. MATERIALS AND METHODS: Nineteen patients treated for RPLS between July 1, 1984, and March 31, 2009, were included. Patient demographics, histopathologic subtypes, survival rate, disease recurrence rate and interval, and adjuvant therapy were reviewed and analyzed. RESULTS: Of the 19 patients diagnosed with RPLS, 26.3% presented with well-differentiated RPLS, 10.5% with dedifferentiated RPLS, 15.8% with myxoid/round cell type, and 47.4% with mixed-type liposarcoma. The mean follow-up period was 66.8 months (range, 6 to 165 months). Primary RPLS was treated in 17 patients. Nine patients (52.9%) had recurrent disease, and recurrence developed at a mean of 47.7 months after primary or repeated surgical treatment. The overall survival rate was 84.2% during a mean follow-up of 66.8 months. The 3- and 5-year survival rates were 86.9%, and the 10-year survival rate was 69.5%. The recurrence interval was significantly shorter in recurrent RPLS cases (p=0.023). The mean growth rate of locally recurrent tumors was 0.34 cm per month. CONCLUSIONS: The survival rates reported here were higher than in previous studies. Locally recurrent tumors presented with a low growth rate, which may have contributed to the relatively high survival rate. A high prevalence of mixed-type RPLS was also noted, and its cause and prognosis require further research.
Authors: Nitesh N Paryani; Robert A Zlotecki; Erika L Swanson; Christopher G Morris; Stephen R Grobmyer; Steven N Hochwald; Robert B Marcus; Daniel J Indelicato Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-01 Impact factor: 7.038
Authors: Fritz C Eilber; Frederick R Eilber; Jeffery Eckardt; Gerald Rosen; Elyn Riedel; Robert G Maki; Murray F Brennan; Samuel Singer Journal: Ann Surg Date: 2004-10 Impact factor: 12.969
Authors: Ronald S A de Vreeze; Daphne de Jong; Ivon H G Tielen; Henrique J Ruijter; Petra M Nederlof; Rick L Haas; Frits van Coevorden Journal: Mod Pathol Date: 2008-09-26 Impact factor: 7.842
Authors: Mooyoung Sohn; Taekmin Kwon; In Gab Jeong; Sungwoo Hong; Dalsan You; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim Journal: Korean J Urol Date: 2014-11-28
Authors: Filipe Rocha Da Silva; Alan Vitor Jerônimo Lima; Erick Willian Rocha Pereira Albuquerque; Carlos Augusto Moreira-Silva; Nicole Maués Flexa De Oliveira; Jorge Alberto Langbeck Ohana; Luís Eduardo Werneck Carvalho Journal: Case Rep Oncol Date: 2018-05-31